Skip to main content

Advertisement

SpringerLink
Log in

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Parathyroid hormone (PTH) is a new treatment for osteoporosis and has been shown to reduce the risks of vertebral and non-vertebral fractures in postmenopausal women in clinical trials. The objective of this study was to estimate the cost-effectiveness of teriparatide in addition to calcium and vitamin D, using a simulation model. The base case analysis was conducted for a cohort of 69-year-old women in Sweden who had at least one previous vertebral fracture and low bone mineral density. The model simulated the course of events in 6-month cycles in individual patients until death or 100 years of age. During each cycle the patients were at risk of experiencing clinical vertebral, hip or wrist fractures, or death. Total accumulated life-time costs and quality-adjusted life years (QALYs) were estimated. Swedish data on fracture costs, utility reductions after fracture, fracture risks and mortality rates were used. The model incorporated new epidemiological evidence that indicates fracture risks and mortality rates are higher in the subsequent years post-fracture. The results showed that the cost-effectiveness of the treatment is highly dependant on the risk profile of the treated patients and the timing of starting treatment relative to previous fractures. The cost per QALY gained for treatment of a population of 69-year-olds with a T-score at the femoral neck of −3 was in the base case estimated to be between EUR (€) 20,000 and 64,000 for patients with a recent or historic vertebral fracture respectively. The study provides further evidence of the benefit and cost-effectiveness of starting osteoporotic treatments early in patients with a new fracture, and also that teriparatide may provide valuable clinical benefits for these patients and may be considered a cost-effective intervention when targeted to the appropriate patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4 a
Fig. 5

Similar content being viewed by others

References

  1. Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

    Google Scholar 

  2. Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14 [Suppl 1]:S1–8

    Google Scholar 

  3. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124

    Google Scholar 

  4. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Google Scholar 

  5. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535

    Google Scholar 

  6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.

    Google Scholar 

  7. Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Incident vertebral fractures during an 18-month observation period following discontinuation of ly333334 [recombinant human parathyroid hormone (1–34), rhPTH (1–34] use in postmenopausal women with osteoporosis. J Bone Min Res 16 [Suppl 1]:S163

  8. Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Maintenance of reduction in nonvertebral fragility fractures 18 months after discontinuation of recombinant human parathyroid hormode (1–34) use in postmenopausal women with osteoporosis. Osteoprosos Int 12 [Suppl 2]:S46

  9. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23

    Google Scholar 

  10. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179

    Google Scholar 

  11. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42

    Google Scholar 

  12. Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857

    Google Scholar 

  13. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Google Scholar 

  14. Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142

    Google Scholar 

  15. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365

    Google Scholar 

  16. Zethraeus N, Jönsson B, Lindgren P (2000) A computer model to analyze the cost-effectiveness of hormone replacement therapy—a revised version. Stockholm: Economic Research Insitute (EFI)

  17. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674

    Google Scholar 

  18. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    Google Scholar 

  19. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590

    Google Scholar 

  20. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828

    Google Scholar 

  21. Kanis J, Brazier J, Stevenson M, Calvert N, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, NHS R&D HTA program 6 (29)

    Google Scholar 

  22. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127

    Google Scholar 

  23. (2003) Statistics Sweden. Sweden’s Statistical Databases

  24. Browner WS, Pressman AR, Nevitt MC, Cummings SR (1996) Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156:1521–1525

    Google Scholar 

  25. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473

    Google Scholar 

  26. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17

    Google Scholar 

  27. Zethraeus N (2002) Costs and quality of life associated with osteoporosis related fractures—based on a Swedish pilot study. Stockholm: Centre for Health Economics (Stockholm School of Economics)

  28. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38

    Google Scholar 

  29. (2000) Stadsledningenskontorets redovisningsstab. The municpality of Stockholm. Stockholm: Stockholms stads budgetavräkning

  30. De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72

    Google Scholar 

  31. LINFO (2003) FASS Läkemedel i Sverige (Swedish drug prices). Oslo, Läkemedelsinformation AB

  32. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64

    Google Scholar 

  33. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen 99:646–650

    Google Scholar 

  34. Lundberg L (1999) Health-related quality of life in Sweden. Dissertation. Faculty of Pharmacy, Uppsala University, Uppsala

  35. Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515

    Google Scholar 

  36. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049

    Google Scholar 

  37. Ekman M, Johnell O, Lidgren L (2004) The economic cost of low back pain in Sweden. Forthcoming in Spine

  38. Ekman M, Jönhagen S, Hunsche E, Jönsson L (2004) Burden of illnesss of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. Forthcoming in Acta Orthopaed Scand

    Google Scholar 

  39. Atlas SJ, Nardin RA (2003) Evaluation and treatment of low back pain: an evidence-based approach to clinical care. Muscle Nerve 27:265–284

    Google Scholar 

  40. Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG (2002) The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ 11:71–85

    Google Scholar 

  41. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427

    Google Scholar 

  42. Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630

    Google Scholar 

  43. Melton LJ, 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388

    Google Scholar 

  44. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258

    Google Scholar 

  45. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 6:9–17

    Google Scholar 

  46. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528

    Google Scholar 

  47. Ekman M (2002) Studies in health economics: EFI, Stockholm School of Economics, Stockholm

    Google Scholar 

Download references

Acknowledgements

The study was conducted with financial support from Lilly Europe.

Author information

Authors and Affiliations

  1. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

    J. Lundkvist

  2. UMAS, Department of Orthopedics, Malmö, Sweden

    O. Johnell

  3. Southampton General Hospital, Southampton, UK

    C. Cooper

  4. UK Lilly Research Centre, Erl Wood Manor, Windlesham, UK

    D. Sykes

  5. Stockholm Health Economics, Klarabergsgatan 33, 11121, Stockholm, Sweden

    J. Lundkvist

Authors
  1. J. Lundkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Johnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Sykes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Lundkvist.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundkvist, J., Johnell, O., Cooper, C. et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 17, 201–211 (2006). https://doi.org/10.1007/s00198-005-1959-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-005-1959-4

Keywords

Search

Navigation